ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Arginine

Also written as “8% arginine + Zinc toothpaste”, “arginine/lysine” and “L Arginine”.

Its studies are mostly in Dental Caries · Dentin Sensitivity · Gastro-enteropancreatic neuroendocrine tumor · Peripheral Vascular Diseases · Peripheral Arterial Disease, led by 4 companies.

Drug pageArginine: every studyAll 124 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 18, 20267 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Colgate Palmoliveits history only31 open or runningphase 3since Jun 18, 2026Feb 4, 2015none ahead
POLYSAN Scientific & Technological Pharmaceuticalits history only20 open or runningphase 2since Mar 1, 2019Jan 16, 2017none ahead
Novartis10 open or runningphase 4since Aug 20, 2020Aug 20, 2020none ahead
Pfizerits history only10 open or runningno phasesince Jan 18, 2006Jan 18, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named arginineINNProposed as its International Nonproprietary Name in WHO's List 117
  2. Aug 20, 2020First study: phase 4 study in Gastro-enteropancreatic neuroendocrine tumorFirst studyNCT04524442 · 42 enrolled · Italy, Netherlands, Poland and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Novartis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04524442Gastro-enteropancreatic neuroendocrine tumor · Italy, Netherlands, Poland and more4CompletedNov 18, 202342

How it is read

Names in the registry

  • “8% arginine + Zinc toothpaste”, 1 entry
  • “arginine/lysine”, 1 entry
  • “L Arginine”, 1 entry
  • “Experimental toothpaste containing fluoride and amino acid (arginine)”, 1 entry
  • “arginine sodium succinate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.